NK4 gene therapy combined with cisplatin inhibits tumour growth and metastasis of squamous cell carcinoma

Anticancer Research

Volumn 31, Issue 1, 2011, Pages 105-111

  Matsumoto, Goichi ^a   Omi, Yasushi ^a   Lee, Ushaku ^a   Kubota, Eiro ^a   Tabata, Yasuhiko ^b  

^a KANAGAWA DENTAL COLLEGE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Cationised gelatin; Cisplatin; Gene therapy; NK4; Squamous cell carcinoma

Indexed keywords

CISPLATIN; MICROSPHERE; PLASMID DNA; PROTEIN NK4; SCATTER FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC GENE THERAPY; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RELEASE; LOW DRUG DOSE; LUNG METASTASIS; MOUSE; MOUTH CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE THERAPY; HEPATOCYTE GROWTH FACTOR; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MICE; MICE, INBRED C3H; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; SKIN NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79851481126     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Parkin DM, Pisani P and Ferlay J: Global cancer statistics. CA Cancer J Clin 49: 33-64, 1999. (Pubitemid 29094960)
2. Greenlee RT, Hill-Harmon MB, Murray T and Thun M: Cancer statistics. CA Cancer J Clin 51: 15-36, 2001.
3. Xi S and Grandis JR: Gene therapy for the treatment of oral squamous cell carcinoma. J Dent Res 82: 11-16, 2003.
4. Kim ES, Kies M and Herbest RS: Novel therapeutics for head and neck cancer. Curr Opin Oncol 14: 334-342, 2002. (Pubitemid 34492868)
5. Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364, 1996. (Pubitemid 26272076)
6. Fidler IJ and Ellis LM: The implication of angiogenesis for the biology and therapy of cancer metastases. Cell 79: 185-188, 1994. (Pubitemid 24324908)
7. Zarnegar R and Michalopoulos GK: The many faces of hepatocyte growth factor: from hepatopoiesis to hematopoiesis. J Cell Biol 129: 1177-1180, 1995.
8. Kim CH, Moon SK, Bae JH, Lee JH, Han JH, Kim K and Choi EC: Expression of hepatocyte growth factor and c-Met in hypopharyngeal squamous cell carcinoma. Acta Otolaryngol 126: 88-94, 2006. (Pubitemid 41769745)
9. Matsumoto K and Nakamura T: Mechanisms and significance of bifunctional NK4 in cancer treatment. Biochem Biophys Res Commun 333: 316-327, 2005. (Pubitemid 40848294)
10. Ikada Y and Tabata Y: Protein release from gelatin materials. Advanced drug delivery reviews 31: 287-301, 1998.
11. Kushibiki T, Tomoshige R, Fukunaka Y, Kakemi M and Tabata Y: In vivo release and gene expression of plasmid DNA by hydrogels of gelatin with different cationization extents. J Control Release 90: 207-216, 2003.
12. Kushibiki T, Nagata-Nakajima N, Sugai M, Shimizu A and Tabata Y: Delivery of plasmid DNA expressing small interference RNA for TGF-beta type II receptor by cationized gelatin to prevent interstitial renal fibrosis. J Control Release 105: 318-331, 2005. (Pubitemid 40941996)
13. Uehara M, Inokuchi T and Sano K: Experimental study of combined hyperthermic and photodynamic therapy on carcinoma in the mouse. J Oral Maxillofac Surg 54: 729-736, 1996.
14. Kuba K, Matsumoto K, Date K, Shimura H, Tanaka M and Nakamura T: HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res 60: 6737-6743, 2000.
15. Kushibiki T, Matsumoto K, Nakamura T and Tabata Y: Suppression of tumor metastasis by NK4 plasmid DNA released from cationized gelatin. Gene Ther 11: 1205-1214, 2004. (Pubitemid 39136784)
16. Kubota T, Taiyoh H, Matsumura A, Murayama Y, Ichikawa D, Okamoto K, Fujiwara H, Ikoma H, Nakanishi M, Kikuchi S, Ochiai T, Sakakura C, Kokuba Y, Sonoyama T, Suzuki Y, Matsumoto K, Nakamura T and Otsuji E: Gene transfer of NK4, an angiogenesis inhibitor, induces CT26 tumor regression via tumor-specific T lymphocyte activation. Int J Cancer 125: 2879-2886, 2009.
17. Kishi Y, Kuba K, Nakamura T, Wen J, Suzuki Y, Mizuno S, Nukiwa T, Matsumoto K and Nakamura T: Systemic NK4 gene therapy inhibits tumor growth and metastasis of melanoma and lung carcinoma in syngeneic mouse tumor models. Cancer Sci 100: 1351-1358, 2009.
18. Wen J, Matsumoto K, Taniura N, Tomioka D and Nakamura T: Inhibition of colon cancer growth and metastasis by NK4 gene repetitive delivery in mice. Biochem Biophys Res Commun 358: 117-123, 2007. (Pubitemid 46719089)
19. Sun X, Krissansen GW, Fung PW, Xu S, Shi J, Man K, Fan ST and Xu R: Anti-angiogenic therapy subsequent to adeno-associated-virus-mediated immunotherapy eradicates lymphomas that disseminate to the liver. Int J Cancer 113: 670-677, 2005. (Pubitemid 40038746)
20. Noro T, Miyake K, Suzuki-Miyake N, Igarashi T, Uchida E, Misawa T, Yamazaki Y and Shimada T: Adeno-associated viral vector-mediated expression of endostatin inhibits tumor growth and metastasis in an orthotropic pancreatic cancer model in hamsters. Cancer Res 64: 7486-7490, 2004. (Pubitemid 39372092)
21. Kushibiki T and Tabata Y: A new gene delivery system based on controlled release technology. Curr Drug Deliv 1: 153-163, 2004.
22. Kushibiki T, Tomoshige R, Fukunaka Y, Kakemi M and Tabata Y: In vivo release and gene expression of plasmid DNA by hydrogels of gelatin with different cationization extents. J Control Release 90: 207-216, 2003.
23. Bello L, Carrabba G, Giussani C, Lucini V, Cerutti F, Scaglione F, Landré J, Pluderi M, Tomei G, Villani R, Carroll RS, Black PM and Bikfalvi A: Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res 61: 7501-7506, 2001. (Pubitemid 32995040)
24. Klement G, Huang P, Mayer B, Green SK, Man S, Bohlen P, Hicklin D and Kerbel RS: Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrog-resistant human breast cancer xenografts. Clin Cancer Res 8: 221-232, 2002. (Pubitemid 34101482)
25. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P and Kerbel RS: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105: 15-24, 2000.
26. Lapidot T and Petit I: Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol 30: 973-981, 2002. (Pubitemid 35286613)
27. Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y and Kerbel RS: Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63: 4342-4346, 2003. (Pubitemid 36951001)
28. Miller KD, Sweeney CJ and Sledge GW Jr.: Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 19: 1195-1206, 2001.